Insider Trading Alert - CTIC, TCBI And FCS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, March 7, 2014, 162 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $252.67 to $79,694,022.59.

Highlighted Stocks Traded by Insiders:

Cell Therapeutics (CTIC) - FREE Research Report

Love Richard L who is Director at Cell Therapeutics sold 40,000 shares at $3.77 on March 7, 2014. Following this transaction, the Director owned 509,265 shares meaning that the stake was reduced by 7.28% with the 40,000-share transaction.

Telling Fred who is Director at Cell Therapeutics sold 72,095 shares at $3.75 on March 7, 2014. Following this transaction, the Director owned 401,170 shares meaning that the stake was reduced by 15.23% with the 72,095-share transaction.

The shares most recently traded at $3.76, up $0.01, or 0.2% since the insider transaction. Historical insider transactions for Cell Therapeutics go as follows:

  • 4-Week # shares sold: 6,000
  • 12-Week # shares sold: 6,000
  • 24-Week # shares sold: 136,551

The average volume for Cell Therapeutics has been 5.5 million shares per day over the past 30 days. Cell Therapeutics has a market cap of $567.1 million and is part of the health care sector and drugs industry. Shares are up 98.43% year-to-date as of the close of trading on Friday.

Cell Therapeutics, Inc. acquires, develops, and commercializes treatments for cancer. Currently there are 2 analysts that rate Cell Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CTIC - FREE

TheStreet Quant Ratings rates Cell Therapeutics as a sell. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Get the full Cell Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Texas Capital (TCBI) - FREE Research Report

Hegi Frederick B Jr who is Director at Texas Capital sold 10,000 shares at $62.68 on March 7, 2014. Following this transaction, the Director owned 33,000 shares meaning that the stake was reduced by 23.26% with the 10,000-share transaction.

The shares most recently traded at $64.86, up $2.18, or 3.36% since the insider transaction. Historical insider transactions for Texas Capital go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 27,075
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 27,075
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 27,075

The average volume for Texas Capital has been 536,800 shares per day over the past 30 days. Texas Capital has a market cap of $2.7 billion and is part of the financial sector and banking industry. Shares are up 2.88% year-to-date as of the close of trading on Friday.

Texas Capital Bancshares, Inc. operates as the bank holding company for Texas Capital Bank, National Association that provides various banking products and services for commercial businesses, and professionals and entrepreneurs in Texas. The company has a P/E ratio of 23.5. Currently there are 6 analysts that rate Texas Capital a buy, no analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TCBI - FREE

TheStreet Quant Ratings rates Texas Capital as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Texas Capital Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Fairchild Semiconductor International (FCS) - FREE Research Report

Thompson Mark who is Ceo at Fairchild Semiconductor International sold 60,000 shares at $13.77 on March 7, 2014. Following this transaction, the Ceo owned 252,399 shares meaning that the stake was reduced by 19.21% with the 60,000-share transaction.

Frey Mark S who is Executive Vice President at Fairchild Semiconductor International sold 49,789 shares at $13.85 on March 7, 2014. Following this transaction, the Executive Vice President owned 54,605 shares meaning that the stake was reduced by 47.69% with the 49,789-share transaction.

The shares most recently traded at $13.86, up $0.01, or 0.07% since the insider transaction. Historical insider transactions for Fairchild Semiconductor International go as follows:

  • 4-Week # shares sold: 15,000
  • 12-Week # shares bought: 20,000
  • 12-Week # shares sold: 15,000
  • 24-Week # shares bought: 20,000
  • 24-Week # shares sold: 32,000

The average volume for Fairchild Semiconductor International has been 974,300 shares per day over the past 30 days. Fairchild Semiconductor International has a market cap of $1.7 billion and is part of the technology sector and electronics industry. Shares are up 4.12% year-to-date as of the close of trading on Friday.

Fairchild Semiconductor International, Inc. designs, develops, manufactures, and sells power analog, power discrete, and non-power semiconductor solutions worldwide. The company has a P/E ratio of 347.5. Currently there are 2 analysts that rate Fairchild Semiconductor International a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FCS - FREE

TheStreet Quant Ratings rates Fairchild Semiconductor International as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and disappointing return on equity. Get the full Fairchild Semiconductor International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home